Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1

Conditions

Hemangioma 3Breast Neoplasms 3Neoplasms 2Heart Failure 2Smoldering Multiple Myeloma 1Postoperative Nausea and Vomiting 1Pain, Postoperative 1Pain 1Ovarian Neoplasms 1Multiple Myeloma 1Hyperalgesia 1Hemangioma, Capillary 1Essential Hypertension 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Adrenergic beta-Antagonists × Clear all
NCT06839144 2025-07-11

OC-POP-PT

Tel-Aviv Sourasky Medical Center

Phase 2 Recruiting
60 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT02215733 2014-08-13

The Use of Angiotensin Receptor Blockers and the Risk of Cancer

Boehringer Ingelheim

Completed
1,165,781 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡